Summary of #ACR20 part A: - HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation - Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS @rheumnow

Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow

Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp

COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs. ⬇️radiographic spinal progression over 2 yrs ⬇️mSASSS progression @RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma

Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment. Abs#2000 #ACR20 @RheumNow https://t.co/lt8xDT4Ne8

• Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Me…

Which DMARD would you use in an RA pt Rx naive pt with mod dz activity and who has RA lung dz? #acr20 @RheumNow

Large cohort of older RA pts newly rx w/HCQ or MTX: 👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ. @RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/ZnDuMhTMYF

HCQ not associated with ⬆ incidence of cardiac dse in this cohort of RA pts. We should continue using it. Benefits >>>risks. @RheumNow #ACR20 abs1999 https://t.co/zYpbX0CsR1